Pepe Jessica, Cecchetti Veronica, Colangelo Luciano, Occhiuto Marco, Santori Rachele, Malaj Krenar, Diacinti Davide, Ettore Evaristo, Desideri Giovambattista, Minisola Salvatore, Cipriani Cristiana
Department of Medical and Cardiovascular Sciences, "Sapienza" University of Rome, Rome, Italy.
University of Vlora Ismail Qemali, Vlora, Albania.
J Endocrinol Invest. 2025 Sep 15. doi: 10.1007/s40618-025-02704-3.
To analyse the effect on fasting glucose levels after one month of PTH 1-34 treatment in postmenopausal women with osteoporosis.
Twenty-six postmenopausal women treated with PTH 1-34 were enrolled. Patients with glucose ≥ 110 mg/dl and/or glycosylated hemoglobin > 48 mmol/mol were excluded. At baseline and after one month treatment, we measured fasting serum glucose, calcium, creatinine, PTH, 25(OH)vitamin D, OPG, RANKL, and BALP. Standardized questionnaires were administered to assess dietary caloric intake and physical activity.
After one month, patients were divided according to the increase (group A) or decrease of glucose (group B). We found no difference between these two groups as regards anthropometric, biochemical evaluation, DXA measurements, dietary caloric intake, physical activity and fractures at baseline. There was no difference between groups in the number of patients treated before with bisphosphonates. Dietary caloric intake and physical activity after one month of therapy were not different in both groups. The mean delta glucose decrease after one month was 7%±4% in group B while the delta increase was 8%±5% in group A, p = 0.001. The only statistically significant difference between these groups, after one month, was an increase in mean delta BALP in group B compared to group A (group B:19 ± 23% vs. group A -0.7 ± 7, p = 0.04). Mean delta vitamin D and OPG increased, while mean delta PTH and RANKL decreased in both groups, without statistically significant differences between groups.
PTH 1-34 decreases mean serum glucose levels when bone formation is increased, as suggested by a significant increase in BALP in this group.
分析甲状旁腺激素1-34（PTH 1-34）治疗1个月对绝经后骨质疏松症女性空腹血糖水平的影响。
招募26例接受PTH 1-34治疗的绝经后女性。排除血糖≥110mg/dl和/或糖化血红蛋白>48mmol/mol的患者。在基线和治疗1个月后，我们测量空腹血清葡萄糖、钙、肌酐、PTH、25(OH)维生素D、骨保护素（OPG）、核因子κB受体活化因子配体（RANKL）和骨碱性磷酸酶（BALP）。采用标准化问卷评估饮食热量摄入和身体活动情况。
1个月后，根据血糖升高（A组）或降低（B组）对患者进行分组。我们发现这两组在基线时的人体测量学、生化评估、双能X线吸收法（DXA）测量、饮食热量摄入、身体活动和骨折情况方面没有差异。两组之前接受双膦酸盐治疗的患者数量没有差异。治疗1个月后，两组的饮食热量摄入和身体活动情况没有差异。B组1个月后平均血糖下降7%±4%，而A组平均血糖升高8%±5%，p=0.001。1个月后，这两组之间唯一具有统计学意义的差异是，与A组相比，B组平均BALP的变化值增加（B组：19±23% vs. A组-0.7±7，p=0.04）。两组的平均维生素D变化值和OPG均升高，而平均PTH变化值和RANKL均降低，两组之间无统计学意义上的差异。
如该组BALP显著升高所示，当骨形成增加时，PTH 1-34可降低平均血清葡萄糖水平。
